269 related articles for article (PubMed ID: 30321187)
41. Functional characterization of naturally occurring transglutaminase 2 mutants implicated in early-onset type 2 diabetes.
Salter NW; Ande SR; Nguyen HK; Nyomba BL; Mishra S
J Mol Endocrinol; 2012 Jun; 48(3):203-16. PubMed ID: 22394545
[TBL] [Abstract][Full Text] [Related]
42. Metastasis-associated S100A4 is a specific amine donor and an activity-independent binding partner of transglutaminase-2.
Biri B; Kiss B; Király R; Schlosser G; Láng O; Kőhidai L; Fésüs L; Nyitray L
Biochem J; 2016 Jan; 473(1):31-42. PubMed ID: 26487698
[TBL] [Abstract][Full Text] [Related]
43. Nucleotide binding kinetics and conformational change analysis of tissue transglutaminase with switchSENSE.
Staffler R; Pasternack R; Hils M; Kaiser W; Möller FM
Anal Biochem; 2020 Sep; 605():113719. PubMed ID: 32697952
[TBL] [Abstract][Full Text] [Related]
44. Intracellular localization and conformational state of transglutaminase 2: implications for cell death.
Gundemir S; Johnson GV
PLoS One; 2009 Jul; 4(7):e6123. PubMed ID: 19568436
[TBL] [Abstract][Full Text] [Related]
45. Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.
van der Wildt B; Lammertsma AA; Drukarch B; Windhorst AD
Amino Acids; 2017 Mar; 49(3):585-595. PubMed ID: 27380031
[TBL] [Abstract][Full Text] [Related]
46. Bcr is a substrate for Transglutaminase 2 cross-linking activity.
Yi SJ; Groffen J; Heisterkamp N
BMC Biochem; 2011 Feb; 12():8. PubMed ID: 21310073
[TBL] [Abstract][Full Text] [Related]
47. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
48. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y
J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646
[TBL] [Abstract][Full Text] [Related]
49. Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases.
Iismaa SE; Holman S; Wouters MA; Lorand L; Graham RM; Husain A
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12636-41. PubMed ID: 14566064
[TBL] [Abstract][Full Text] [Related]
50. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
51. The 55 kDa tissue transglutaminase cross-linking active isoform TG induces cell death.
Fraij BM
Mol Carcinog; 2015 Sep; 54(9):720-9. PubMed ID: 24464646
[TBL] [Abstract][Full Text] [Related]
52. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Grosso H; Mouradian MM
Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
[TBL] [Abstract][Full Text] [Related]
53. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
[TBL] [Abstract][Full Text] [Related]
54. Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.
Navals P; Rangaswamy AMM; Kasyanchyk P; Berezovski MV; Keillor JW
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672511
[TBL] [Abstract][Full Text] [Related]
55. Tissue transglutaminase (TG2) and mitochondrial function and dysfunction.
Lai TS; Lin CJ; Wu YT; Wu CJ
Front Biosci (Landmark Ed); 2017 Mar; 22(7):1114-1137. PubMed ID: 28199195
[TBL] [Abstract][Full Text] [Related]
56. Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.
Thangaraju K; Király R; Demény MA; András Mótyán J; Fuxreiter M; Fésüs L
PLoS One; 2017; 12(3):e0172189. PubMed ID: 28248968
[TBL] [Abstract][Full Text] [Related]
57. Detection of Transglutaminase 2 conformational changes in living cell.
Pavlyukov MS; Antipova NV; Balashova MV; Shakhparonov MI
Biochem Biophys Res Commun; 2012 May; 421(4):773-9. PubMed ID: 22548802
[TBL] [Abstract][Full Text] [Related]
58. Substrate preference of transglutaminase 2 revealed by logistic regression analysis and intrinsic disorder examination.
Csosz E; Bagossi P; Nagy Z; Dosztanyi Z; Simon I; Fesus L
J Mol Biol; 2008 Nov; 383(2):390-402. PubMed ID: 18761350
[TBL] [Abstract][Full Text] [Related]
59. Role of transglutaminase 2 in celiac disease pathogenesis.
Klöck C; Diraimondo TR; Khosla C
Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
[TBL] [Abstract][Full Text] [Related]
60. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation.
Colak G; Keillor JW; Johnson GV
PLoS One; 2011 Jan; 6(1):e16665. PubMed ID: 21304968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
